Imaging PD-L1 Expression in Cancers Using 68Ga-NK224 PET
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
This study is testing a new type of PET scan to see if it can accurately measure a protein in cancer tumors for people who have just been diagnosed or have already been treated for cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Xiamen University Academic / other |
| Locations | 1 site (Xiamen, Fujian) |
| Trial ID | NCT06754345 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) in assessing PD-L1 expression in cancerous tumors. Participants with newly diagnosed or previously treated malignant tumors will undergo PET/CT scans, and the results will be compared to histopathological findings to determine the diagnostic accuracy. The study aims to quantify tumor uptake using maximum and mean standard uptake values (SUVmax and SUVmean).
Who should consider this trial
Good fit: Ideal candidates include adult patients aged 18 or older with newly diagnosed or previously treated malignant tumors scheduled for 68Ga-NK224 PET/CT scans.
Not a fit: Patients with non-malignant lesions or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the accuracy of cancer diagnosis and treatment planning by providing reliable information on PD-L1 expression.
How similar studies have performed: While this specific approach is novel, similar imaging techniques have shown promise in evaluating tumor markers in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (i) adult patients (aged 18 years or order); * (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report); * (iii) patients who had scheduled 68Ga-NK224 PET/CT scans; * (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * (i) patients with non-malignant lesions; * (ii) patients with pregnancy; * (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Xiamen, Fujian
- The First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Liang Zhao
- Email: wzhaoliang01@163.com
- Phone: 86 0592-213-7366
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.